For women with high-risk aPL profiles but no history of thrombosis or pregnancy complications, prophylactic antithrombotic therapy with LDA, 75–100 mg daily, should be considered during pregnancy, particularly given a history of obstetric APS. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.